Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Receivables (2016 - 2025)

Historic Receivables for Ptc Therapeutics (PTCT) over the last 13 years, with Q3 2025 value amounting to $203.1 million.

  • Ptc Therapeutics' Receivables rose 154.92% to $203.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $203.1 million, marking a year-over-year increase of 154.92%. This contributed to the annual value of $158.6 million for FY2024, which is 153.27% down from last year.
  • Per Ptc Therapeutics' latest filing, its Receivables stood at $203.1 million for Q3 2025, which was up 154.92% from $196.1 million recorded in Q2 2025.
  • Ptc Therapeutics' 5-year Receivables high stood at $210.5 million for Q1 2025, and its period low was $78.8 million during Q2 2021.
  • Over the past 5 years, Ptc Therapeutics' median Receivables value was $161.0 million (recorded in 2023), while the average stood at $157.8 million.
  • Its Receivables has fluctuated over the past 5 years, first surged by 7886.48% in 2021, then tumbled by 168.77% in 2024.
  • Quarter analysis of 5 years shows Ptc Therapeutics' Receivables stood at $110.5 million in 2021, then skyrocketed by 40.88% to $155.6 million in 2022, then rose by 3.48% to $161.0 million in 2023, then decreased by 1.53% to $158.6 million in 2024, then rose by 28.08% to $203.1 million in 2025.
  • Its last three reported values are $203.1 million in Q3 2025, $196.1 million for Q2 2025, and $210.5 million during Q1 2025.